JP2013508382A5 - - Google Patents

Download PDF

Info

Publication number
JP2013508382A5
JP2013508382A5 JP2012535319A JP2012535319A JP2013508382A5 JP 2013508382 A5 JP2013508382 A5 JP 2013508382A5 JP 2012535319 A JP2012535319 A JP 2012535319A JP 2012535319 A JP2012535319 A JP 2012535319A JP 2013508382 A5 JP2013508382 A5 JP 2013508382A5
Authority
JP
Japan
Prior art keywords
ethyl
methyl
pharmaceutically acceptable
dihydropyrido
tetrahydropyran
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012535319A
Other languages
English (en)
Other versions
JP5581390B2 (ja
JP2013508382A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/053295 external-priority patent/WO2011050016A1/en
Publication of JP2013508382A publication Critical patent/JP2013508382A/ja
Publication of JP2013508382A5 publication Critical patent/JP2013508382A5/ja
Application granted granted Critical
Publication of JP5581390B2 publication Critical patent/JP5581390B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Claims (3)

  1. 以下の式の化合物:
    Figure 2013508382
    [式中、
    Aは
    Figure 2013508382
    または
    Figure 2013508382
    であり、
    は、CH、CHCHまたはCFであり;
    は、H、CF、CHCF、CHCHCF、C−Cアルキル、C−Cシクロアルキル、CN、Cl、Br、CH=CH、CHCHOCH、C(CHCHOCHまたはテトラヒドロピラン−4−イルであり、ここでC−Cシクロアルキルは1位においてメチルで任意に置換され、テトラヒドロピラン−4−イルは4位においてメチルで任意に置換され、RはHであり;
    またはRおよびRは両方Clであり;
    はHであり、RはCH、C(CH、CH(CH、シクロブチル、シクロペンチル、CH−シクロプロピル、C(CHCHCHまたはテトラヒドロピラン−4−イルであり;
    またはRおよびRは両方CHであり;
    またはRおよびRは、それらが結合するNと一緒に3位においてヒドロキシで任意に置換されるピロリジン、またはアゼチジンを形成する]
    またはその医薬的に許容可能な塩。
  2. (R)−5−メチル−4−(4−(1−(2−(ピロリジン−1−イル)エチル)−4−(3,3,3−トリフルオロプロピル)−1H−イミダゾール−2−イル)ピペリジン−1−イル)−5,6−ジヒドロピリド[2,3−d]ピリミジン−7(8H)−オン;
    (R)−4−(4−(4−エチル−1−(2−(ピロリジン−1−イル)エチル)−1H−イミダゾール−2−イル)ピペリジン−1−イル)−5−メチル−5,6−ジヒドロピリド[2,3−d]ピリミジン−7(8H)−オン;および
    (R)−4−(4−(1−(2−(アゼチジン−1−イル)エチル)−4−(2,2,2−トリフルオロメチル)−1H−イミダゾール−2−イル)ピペリジン−1−イル)−5−(トリフルオロメチル)−5,6−ジヒドロピリド[2,3−d]ピリミジン−7(8H)−オン
    から選択される請求項1に記載の化合物またはその医薬的に許容可能な塩。
  3. 請求項1または2に記載の化合物、またはその医薬的に許容可能な塩、および医薬的に許容可能な担体、希釈剤または賦形剤を含む、肺癌、乳癌または膠芽細胞腫を治療するための医薬製剤。
JP2012535319A 2009-10-23 2010-10-20 Akt阻害剤 Expired - Fee Related JP5581390B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25430809P 2009-10-23 2009-10-23
US61/254,308 2009-10-23
PCT/US2010/053295 WO2011050016A1 (en) 2009-10-23 2010-10-20 Akt inhibitors

Publications (3)

Publication Number Publication Date
JP2013508382A JP2013508382A (ja) 2013-03-07
JP2013508382A5 true JP2013508382A5 (ja) 2013-06-06
JP5581390B2 JP5581390B2 (ja) 2014-08-27

Family

ID=43467018

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012535319A Expired - Fee Related JP5581390B2 (ja) 2009-10-23 2010-10-20 Akt阻害剤

Country Status (12)

Country Link
US (1) US8436002B2 (ja)
EP (1) EP2491032B1 (ja)
JP (1) JP5581390B2 (ja)
KR (1) KR101398268B1 (ja)
CN (1) CN102574852B (ja)
AU (1) AU2010310786B2 (ja)
BR (1) BR112012011328A2 (ja)
CA (1) CA2778291C (ja)
EA (1) EA020151B1 (ja)
ES (1) ES2465094T3 (ja)
MX (1) MX2012004780A (ja)
WO (1) WO2011050016A1 (ja)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA37647A1 (fr) 2012-05-17 2016-03-31 Genentech Inc Procédé de fabrication de composés de cyclopentapyrimidine hydroxylée et sels de ceux-ci
BR112014028593A2 (pt) 2012-05-17 2017-12-19 Genentech Inc forma amorfa de um composto de pirimidinil-ciclopentano inibidor de akt, composições e métodos dos mesmos"
CN104487430B (zh) 2012-05-17 2016-08-24 阵列生物制药公司 用于制造羟基化的环戊基嘧啶化合物的方法
CA2873658C (en) 2012-05-17 2021-01-26 Genentech, Inc. Process for making amino acid compounds
CA2873654C (en) * 2012-05-17 2021-06-22 Array Biopharma Inc. Process for making hydroxylated cyclopentylpyrimidine compounds
EP2920154B1 (en) * 2012-11-16 2017-10-11 Merck Patent GmbH Novel imidazol-piperidinyl derivatives as modulators of kinase activity
SG10201900954SA (en) * 2013-03-11 2019-02-27 Merck Patent Gmbh Heterocycles as Modulators of Kinase Activity
WO2015013579A1 (en) 2013-07-26 2015-01-29 Update Pharma Inc. Compositions to improve the therapeutic benefit of bisantrene
US10526660B2 (en) 2013-09-12 2020-01-07 Dana-Farber Cancer Institute, Inc. Methods for evaluating and treating Waldenstrom's macroglobulinemia
GB201401198D0 (en) 2014-01-24 2014-03-12 Bial Portela & Ca Sa Process for the syntheis of substituted urea compounds
EP3110509B1 (en) 2014-02-28 2020-08-19 Merck Sharp & Dohme Corp. Treating cancer with a combination comprising dinaciclib
EP3459953B1 (en) * 2016-05-20 2021-06-30 Taiho Pharmaceutical Co., Ltd. Novel 5h-pyrrolo[2,3-d]pyrimidin-6(7h)-one derivative
EP3919491A4 (en) * 2019-01-29 2022-10-19 Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. AKT INHIBITOR
WO2021228223A1 (zh) * 2020-05-15 2021-11-18 南京正大天晴制药有限公司 氘代akt激酶抑制剂
JP7499942B2 (ja) 2020-07-22 2024-06-14 南京正大天晴制薬有限公司 ジヒドロピリド[2,3-d]ピリミジノン誘導体の塩、その調製方法及び用途
US20230271958A1 (en) * 2020-07-22 2023-08-31 Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. SALT AND CRYSTAL FORM OF DIHYDROPYRIDO[2,3-d]PYRIMIDINE DERIVATE
CN115916350A (zh) * 2020-07-22 2023-04-04 南京正大天晴制药有限公司 Akt抑制剂的单位剂量组合物

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4128089A (en) 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
GB9300059D0 (en) 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
GB9221220D0 (en) 1992-10-09 1992-11-25 Sandoz Ag Organic componds
US5362718A (en) 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
NL1004346C2 (nl) 1996-10-23 1998-04-24 Dsm Nv Werkwijze voor het scheiden van een mengsel van enantiomeren in een geschikt oplosmiddel.
KR100956195B1 (ko) 2002-02-01 2010-05-06 어리어드 파마슈티칼스, 인코포레이티드 인 함유 화합물 및 이의 용도
US7563748B2 (en) 2003-06-23 2009-07-21 Cognis Ip Management Gmbh Alcohol alkoxylate carriers for pesticide active ingredients
US8076338B2 (en) 2004-04-23 2011-12-13 Exelixis, Inc. Kinase modulators and methods of use
WO2006000020A1 (en) 2004-06-29 2006-01-05 European Nickel Plc Improved leaching of base metals
MY179032A (en) 2004-10-25 2020-10-26 Cancer Research Tech Ltd Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
AU2005316668B2 (en) * 2004-12-13 2012-09-06 Millennium Pharmaceuticals, Inc. Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as RAF kinase inhibitors
EP1848719B1 (en) 2004-12-28 2012-02-01 Exelixis, Inc. [1h-pyrazolo[3,4-d]pyrimidin-4-yl]-piperidine or -piperazine compounds as serine-threonine kinase modulators (p70s6k, atk1 and atk2) for the treatment of immunological, inflammatory and proliferative diseases
CN101227857B (zh) 2005-06-29 2011-10-19 电脑医师有限公司 具有导电桥的传感器组件
WO2007125325A1 (en) * 2006-04-25 2007-11-08 Astex Therapeutics Limited Pharmaceutical compounds
EP3421471B1 (en) 2006-04-25 2021-05-26 Astex Therapeutics Limited Purine and deazapurine derivatives as pharmaceutical compounds
TW200801513A (en) 2006-06-29 2008-01-01 Fermiscan Australia Pty Ltd Improved process
AR064416A1 (es) * 2006-12-21 2009-04-01 Cancer Rec Tech Ltd Derivados de purina, piridina y pirimidina condensadas con heterociclos, moduladores de pka y/o pkb, composiciones farmaceuticas que los contienen, y usos para el tratamiento de enfermedades hiperproliferativas.
UA99284C2 (ru) * 2007-05-11 2012-08-10 Елі Ліллі Енд Компані ИНГИБИТОРЫ р70 S6-КИНАЗЫ
AR074072A1 (es) * 2008-11-11 2010-12-22 Lilly Co Eli Compuesto de imidazol -piperidin -pirrol-pirimidin-6-ona, composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para tratar el glioblastoma multiforme

Similar Documents

Publication Publication Date Title
JP2013508382A5 (ja)
AU2017260363B2 (en) Modulators of the integrated stress pathway
JP2010540509A5 (ja)
JP2019077725A5 (ja)
HRP20171696T1 (hr) 3,4-dihidroizokinolin-2(1h)-ilni spojevi
JP2009542613A5 (ja)
JP2008513498A5 (ja)
JP2013510124A5 (ja)
JP2008535902A5 (ja)
JP2006524660A5 (ja)
JP2013510120A5 (ja)
JP2011509309A5 (ja)
JP2015529235A5 (ja)
JP2009532452A5 (ja)
JP2008525417A5 (ja)
JP2011500758A5 (ja)
JP2010241830A5 (ja)
JP2016506962A5 (ja)
JP2010523681A5 (ja)
EP2620432A3 (en) Diarylhydantoin compounds
JP2010515715A5 (ja)
CN112041307B (zh) 作为选择性雌激素受体降解剂的取代的苯并噻吩类似物
JP2011507896A5 (ja)
RU2017118165A (ru) Ингибиторы энхансера гомолога 2 zestes
JP2015524450A5 (ja)